0001415889-15-000615.txt : 20150219
0001415889-15-000615.hdr.sgml : 20150219
20150219180008
ACCESSION NUMBER: 0001415889-15-000615
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150217
FILED AS OF DATE: 20150219
DATE AS OF CHANGE: 20150219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11085 TORREYANA ROAD
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 11085 TORREYANA ROAD
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rasmussen Torsten
CENTRAL INDEX KEY: 0001291881
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 15632970
MAIL ADDRESS:
STREET 1: SMEDENS AGER 6
STREET 2: NORUP
CITY: DK-7182 BREDSTEN
STATE: G7
ZIP: DK-7182
4
1
form4-02192015_030200.xml
X0306
4
2015-02-17
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001291881
Rasmussen Torsten
11085 TORREYANA ROAD #100
SAN DIEGO
CA
92121
true
false
false
false
Common Stock
2015-02-17
4
M
0
2780
8.49
A
11280
I
See footnote
Common Stock
2015-02-17
4
M
0
7067
8.49
A
18347
I
See footnote
Common Stock
2015-02-17
4
M
0
10000
1.36
A
28347
I
See footnote
Common Stock
2015-02-17
4
S
0
19847
35.0453
D
8500
I
See footnote
Stock option (right to buy)
8.49
2015-02-17
4
M
0
2780
0
D
2018-06-12
Common Stock
2780
0
I
See footnote
Stock option (right to buy)
8.49
2015-02-17
4
M
0
7067
0
D
2018-06-12
Common Stock
7067
0
I
See footnote
Stock option (right to buy)
1.36
2015-02-17
4
M
0
10000
0
D
2022-06-07
Common Stock
10000
0
I
See footnote
Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.10 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.
25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 8, 2012.
/s/ Glenn F. Baity, Attorney-in-Fact
2015-02-19